# Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

> **NCT03817515** · — · APPROVED_FOR_MARKETING · sponsor: **Aadi Bioscience, Inc.**

## Conditions studied

- PEComa, Malignant
- TSC1
- TSC2
- mTOR Pathway Abberation

## Interventions

- **DRUG:** ABI-009

## Key facts

- **NCT ID:** NCT03817515
- **Lead sponsor:** Aadi Bioscience, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** EXPANDED_ACCESS
- **Status:** APPROVED_FOR_MARKETING
- **Start date:** —
- **Primary completion:** —
- **Final completion:** —
- **Target enrollment:** — (—)
- **Last updated:** 2022-03-16


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03817515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03817515, "Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03817515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*